Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Cited by (999)

Items 601–700 of 999

1. Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A
   Eduard Dolušić, Pierre Larrieu, Céline Meinguet, Delphine Colette, Arnaud Rives, Sébastien Blanc, Thierry Ferain, Luc Pilotte, Vincent Stroobant, Johan Wouters et al. · 2012 · Bioorganic & Medicinal Chemistry Letters
2. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans
   Michael Stapelberg, Renata Zobalová, Maria Nga Nguyen, Tom Walker, Marina Stantic, Jacob Goodwin, Elham Alizadeh Pasdar, Thuan Thai, Kateřina Rohlenová, Bing Yan et al. · 2013 · Free Radical Biology and Medicine
3. Metabolomics for Biomarker Discovery in Gastroenterological Cancer
   Shin Nishiumi, Makoto Suzuki, Takashi Kobayashi, Atsuki Matsubara, Takeshi Azuma, Masaru Yoshida · 2014 · Metabolites
4. Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
   Longfei Mao, Yuwei Wang, Jie Zhao, Guiqing Xu, Xiaojun Yao, Yue-Ming Li · 2020 · Frontiers in Pharmacology
5. Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan
   Jun Zeng, Shaohui Cai, Yanmei Yi, Yuwen He, Zhen Wang, Guangmin Jiang, Xiaokun Li, Jun Du · 2009 · Cancer Research
6. The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1
   Hollie E. Flick, Judith M. LaLonde, William P. Malachowski, Alexander J. Muller · 2013 · International Journal of Tryptophan Research
7. How interacting pathways are regulated by miRNAs in breast cancer subtypes
   Claudia Cava, Antonio Colaprico, Gloria Rita Bertoli, Gianluca Bontempi, Giancarlo Mauri, Isabella Castiglioni · 2016 · BMC Bioinformatics
8. Kynurenines as a Novel Target for the Treatment of Malignancies
   Adrian Mor, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak · 2021 · Pharmaceuticals
9. Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue
   Takeaki Okamoto, S. Toné, H. Kanouchi, C. Miyawaki, Sayuri Ono, Y. Minatogawa · 2007 · Cytotechnology (Dordrecht)
10. Development of a mouse model of mammary gland versus uterus tissue selectivity using estrogen- and progesterone-regulated gene markers
    Judy S. Crabtree, Xiaochun Zhang, Bryan J. Peano, Zhiming Zhang, Richard C. Winneker, Heather A. Harris · 2006 · The Journal of Steroid Biochemistry and Molecular Biology
11. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer
    Qian Ye, Chenglong Wang, Jie Xian, Ming Zhang, Yijia Cao, Youde Cao · 2018 · Human Pathology
12. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion
    Li-Lian Gan, Ling‐Wei Hii, Shew Fung Wong, Chee‐Onn Leong, Chun‐Wai Mai · 2020 · Cancers
13. An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
    Simone Ragaini, Sarah Wagner, Giovanni Marconi, Sarah Parisi, Chiara Sartor, Jacopo Nanni, Gianluca Cristiano, Annalisa Talami, Matteo Olivi, Darina Očadlíková et al. · 2021 · Blood Advances
14. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
    Kai Tang, Bo Wang, Bin Yu, Hong‐Min Liu · 2021 · European Journal of Medicinal Chemistry
15. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
    John D. Powderly, Samuel Jacob Klempner, Aung Naing, Johanna C. Bendell, Ignacio Garrido‐Laguna, Daniel V.T. Catenacci, Matthew Hiram Taylor, James J. Lee, Fred Zheng, Feng Zhou et al. · 2022 · The Oncologist
16. The mechanisms on evasion of anti-tumor immune responses in gastric cancer
    Junyang Wang, Tong Liu, Tao Huang, Mei Shang, Xudong Wang · 2022 · Frontiers in Oncology
17. Identification of a Variable Number of Tandem Repeats Polymorphism and Characterization of LEF-1 Response Elements in the Promoter of the IDO1 Gene
    Marion Soichot, Benjamin Hennart, Alaa Al Saabi, Audrey Leloire, Philippe Froguel, Claire Lévy‐Marchal, Odile Poulain‐Godefroy, Delphine Allorge · 2011 · PLoS ONE
18. The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy
    Trevor W. Stone, Lynda Gail Darlington, Abdulla A.‐B. Badawy, Richard O. Williams · 2024 · International Journal of Molecular Sciences
19. Synthesis of [18F] 4‐amino‐N‐(3‐chloro‐4‐fluorophenyl)‐N′‐hydroxy‐1,2,5‐oxadiazole‐3‐carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression
    Xuan Huang, Robert J. Gillies, Haibin Tian · 2015 · Journal of Labelled Compounds and Radiopharmaceuticals
20. General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation
    Melanie Keil, Jana K. Sonner, Tobias Volker Lanz, Iris Oezen, Theresa Bunse, Stefan Bittner, Hannah V. Meyer, Sven Guenther Meuth, Wolfgang Wick, Michael Platten · 2016 · Journal of Neuroimmunology
21. A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies
    Alessia Griglio, Enza Torre, M. Teresa Serafini, Alice Bianchi, Roberta Schmid, Giulia Coda Zabetta, Alberto Massarotti, Giovanni Sorba, Tracey Pirali, Silvia Fallarini · 2018 · Bioorganic & Medicinal Chemistry Letters
22. Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment
    Yang Xu, Hui-Kai Zhang, Qian Sun, Rong-Xin Geng, Fan'en Yuan, Bao-Hui Liu, Qian-Xue Chen · 2021 · Frontiers in Immunology
23. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase
    Jiangxin Liu, Jian Xing Ren, Kun Yang, Shuang Chen, Xinni Yang, Qin‐Shi Zhao · 2022 · European Journal of Medicinal Chemistry
24. Expression of Indoleamine 2,3-Dioxygenase and Infiltration of FOXP3+ Regulatory T Cells Are Associated with Aggressive Features of Papillary Thyroid Microcarcinoma
    Han Suk Ryu, Young Soo Park, Hyo Jin Park, Yul Ri Chung, Cha Kyong Yom, Soon‐Hyun Ahn, Young Joo Park, Seong Hoe Park, So Yeon Park · 2014 · Thyroid
25. Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells
    Ting Sun, Xianghua Chen, Zheng-De Tang, Jiong Cai, Xiaoyan Wang, Shih-Chen Wang, Zhao-Long Li · 2010 · Molecular and Cellular Biochemistry
26. Lignans from Carthamus tinctorius suppress tryptophan breakdown via indoleamine 2,3-dioxygenase
    Susanne Kuehnl, S. Schroecksnadel, V. Temml, J. Gostner, H. Schennach, D. Schuster, S. Schwaiger, J. Rollinger, D. Fuchs, H. Stuppner · 2013 · Phytomedicine
27. FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Noritoshi Kobayashi, Kensuke Kubota, Shingo Kato, Seitaro Watanabe, Takeshi Shimamura, Hiroyuki Kirikoshi, Satoru Saito, Michio Ueda, Itaru Endo, Yoshiaki lnayama et al. · 2010 · Pancreatology
28. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?
    Stefan Löb, Alfred Königsrainer · 2007 · Langenbeck s Archives of Surgery
29. No cancer in cancers: Evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system
    Satoshi Hayakawa · 2006 · Medical Hypotheses
30. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
    Elizabeth S. McKenna, Pablo Tamayo, Yoon‐Jae Cho, Erik J. Tillman, E. Lorena Mora‐Blanco, Courtney G. Sansam, Edward C. Koellhoffer, Scott L. Pomeroy, Charles W.M. Roberts · 2012 · Cell Cycle
31. Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors
    Shulun Chen, Wei Guo, Xiaohua Liu, Pu Sun, Yi Wang, Chunyong Ding, Linghua Meng, Ao Zhang · 2019 · European Journal of Medicinal Chemistry
32. Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo
    Kathleen M. McAvoy, Hameetha Rajamohamed Sait, Galina Marsh, Michael A. Peterson, Taylor L. Reynolds, Jake Gagnon, Sarah B. Geisler, Prescott T. Leach, Chris Roberts, Ellen D. Cahir-McFarland et al. · 2019 · PLoS ONE
33. Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy
    Anna C. Beielstein, Christian Philipp Pallasch · 2019 · International Journal of Molecular Sciences
34. The aryl hydrocarbon receptor in tumor immunity
    Michael Platten, Ulrike M. Litzenburger, Wolfgang Wick · 2012 · OncoImmunology
35. Molecular Evolution and Characterization of Fungal Indoleamine 2,3-Dioxygenases
    Hajime Julie Yuasa, Helen J. Ball · 2010 · Journal of Molecular Evolution
36. Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ
    Anna Maria Gasparri, Elena Jachetti, Barbara Colombo, Angelina Sacchi, Flavio Curnis, Gian‐Paolo Rizzardi, Catia Traversari, Matteo Bellone, Angelo Corti · 2008 · Molecular Cancer Therapeutics
37. Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives
    Georgios Pantouris, James Loudon-Griffiths, Christopher G. Mowat · 2016 · Journal of Enzyme Inhibition and Medicinal Chemistry
38. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition
    Xuexiao Wang, Jiali Wang, Yunlong Jia, Yu Wang, Xiaonan Han, Yuqing Duan, Wei Lv, Ming Ma, Lihua Liu · 2017 · Oncotarget
39. Evidence accumulating in support of cancer vaccines combined with chemotherapy: A pragmatic review of past and present efforts
    Joseph Sinkovics, Joseph C. Horvath · 2006 · International Journal of Oncology
40. Halicloic Acids A and B Isolated from the Marine Sponge Haliclona sp. Collected in the Philippines Inhibit Indoleamine 2,3-Dioxygenase
    David E. Williams, Anne Steinø, Nicole Joy de Voogd, A. Grant Mauk, Raymond J. Andersen · 2012 · Journal of Natural Products
41. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models
    Shanyue Sun, Guangying Du, Jiang Xue, Jinbo Ma, Minmin Ge, Hongbo Wang, Jingwei Tian · 2018 · International Journal of Immunopathology and Pharmacology
42. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel
    Jian Zhi Xu, Xiaohong Ren, Tao Guo, Xian Sun, Xiaojin Chen, Laurence H. Patterson, Haiyan Li, Jiwen Zhang · 2019 · European Journal of Pharmaceutical Sciences
43. Rational design of anticancer platinum(IV) prodrugs
    Shuren Zhang, Xiaoyong Wang, Zijian Guo · 2019 · Advances in inorganic chemistry
44. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
    Qing-Zhu Fan, Ji Zhou, Yi‐Bao Zhu, Lianjun He, Dong‐Dong Miao, Shengpeng Zhang, Xiaoping Liu, Chao Zhang · 2020 · Bioorganic Chemistry
45. IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation
    Alexander J. Muller, Arpita Mondal, Souvik Dey, George C. Prendergast · 2023 · Frontiers in Oncology
46. Uterine microbial communities and their potential role in the regulation of epithelium cell cycle and apoptosis in aged hens
    Dong Dai, Jing Wang, Haijun Zhang, Shugeng Wu, Guanghai Qi · 2023 · Microbiome
47. Benzomalvin E, an indoleamine 2,3-dioxygenase inhibitor isolated from Penicillium sp. FN070315
    Jun‐Pil Jang, Jae‐Hyuk Jang, Nak‐Kyun Soung, Hye-Min Kim, Sook-Jung Jeong, Yukihiro Asami, Kee‐Sun Shin, Mee Ree Kim, Hyuncheol Oh, Bo Yeon Kim et al. · 2012 · The Journal of Antibiotics
48. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis
    Yuhei Shibata, Takeshi Hara, Junji Nagano, Nobuhiko Nakamura, Tomohiko Ohno, Soranobu Ninomiya, Hiroyasu Ito, Takuji Tanaka, Kuniaki Saito, Mitsuru Seishima et al. · 2016 · PLoS ONE
49. Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
    A. Engin, I. Gonul, A. Engin, A. Karamercan, A. Sepici-Dinçel, A. Dursun · 2016 · World Journal of Gastroenterology
50. Activation of the tryptophan/serotonin pathway is associated with severity and predicts outcomes in pneumonia: results of a long-term cohort study
    Marc A. Meier, Manuel Ottiger, Alaadin Vögeli, Christian Steuer, Luca Bernasconi, Robert Thomann, Mirjam Christ‐Crain, Christoph Henzen, Claus Hoess, Werner Zimmerli et al. · 2017 · Clinical Chemistry and Laboratory Medicine (CCLM)
51. Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model
    Yanling Liu, Ping Xu, Huan Liu, Chunjuan Fang, Haihe Guo, Xiaoyan Chen, Manman Tan, Yujuan Zhang, Wei‐Ping Min · 2020 · International Journal of Oncology
52. Ferryl Derivatives of Human Indoleamine 2,3-Dioxygenase
    Changyuan Lu, Syun‐Ru Yeh · 2011 · Journal of Biological Chemistry
53. Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab
    Basma M. Sharaf, Alexander D. Giddey, Hasan Yaser Alniss, Hamza Mohammad Al-Hroub, Raafat El‐Awady, Muath Mousa, Ahmed M. Almehdi, Nelson Cruz Soares, Mohammad Harb Semreen · 2021 · Cancer Genomics & Proteomics
54. Unwinding the modalities of necrosome activation and necroptosis machinery in neurological diseases
    Rohan V. Gupta, Smita Kumari, Rahul S. Tripathi, Rashmi K. Ambasta, Pravir Kumar · 2023 · Ageing Research Reviews
55. Interplay between Estrogen, Kynurenine, and AHR Pathways: An immunosuppressive axis with therapeutic potential for breast cancer treatment
    Jorge H. Limón-Pacheco, Guillermo Elizondo · 2023 · Biochemical Pharmacology
56. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation
    A. Muller, L. Mandik-Nayak, G. Prendergast · 2010 · Immunotherapy
57. Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer
    Fangxuan Li, Lijuan Wei, Shixia Li, Juntian Liu · 2017 · Oncotarget
58. Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA
    Kun Fang, Guoqiang Dong, Hongyu Wang, Shipeng He, Shanchao Wu, Wei Wang, Chunquan Sheng · 2017 · ChemMedChem
59. Induction of indoleamine 2,3-dioxygenase expression via heme oxygenase-1-dependant pathway during murine dendritic cell maturation
    In Duk Jung, Jun Sik Lee, Chang‐Min Lee, Kyung Tae Noh, Yeong-Il Jeong, Won Sun Park, Sung Hak Chun, Soo Kyung Jeong, Jin Wook Park, Kwang Hee Son et al. · 2010 · Biochemical Pharmacology
60. Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation
    Catarina Carvalho, David M. Siegel, Martyn W. Inman, Rui Xiong, David Ross, Christopher J. Moody · 2014 · Organic & Biomolecular Chemistry
61. The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection
    Levi Makala · 2012 · Journal of Biomedical Science
62. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy
    Zihua Hu, Binbin Zheng, Jiaojiao Xu, Shuai Gao, Wei Lü · 2020 · Nanotechnology
63. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
    Nobuhiko Nakamura, Takeshi Hara, Masahito Shimizu, Ryoko Mabuchi, Junji Nagano, Tomohiko Ohno, Takahiro Kochi, Masaya Kubota, Yohei Shirakami, Naoe Goto et al. · 2015 · International Journal of Hematology
64. Catalytic activity of human indoleamine 2,3-dioxygenase (hIDO1) at low oxygen
    Ayodele Oluseyi Kolawole, Brian P Hixon, Laura S Dameron, Ian M. Chrisman, Valeriy V. Smirnov · 2015 · Archives of Biochemistry and Biophysics
65. Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors
    Hitomi Nakashima, Yoshihiro Uto, Eiji Nakata, Hideko Nagasawa, Kazuhiro Ikkyu, Noriko Hiraoka, Kouichiro Nakashima, Yuki Sasaki, Hiroshi Sugimoto, Yoshitsugu Shiro et al. · 2008 · Bioorganic & Medicinal Chemistry
66. Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer
    Awalpreet Singh Chadha, Allison Khoo, Maureen L. Aliru, Harpreet K. Arora, Jillian Rebecca Gunther, Sunil Krishnan · 2016 · Seminars in Radiation Oncology
67. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles
    P. Calleja, Juan M. Irache, Carolina Zandueta, María Cristina Martínez-Ohárriz, Socorro Espuelas · 2017 · Pharmacological Research
68. Ambivalent effects of dendritic cells displaying prostaglandin E 2‐induced indoleamine 2,3‐dioxygenase
    Margit Lanzinger, Birgit Jürgens, Ursula Hainz, Barbara Dillinger, Julia Raberger, Dietmar Fuchs, Andreas Heitger · 2012 · European Journal of Immunology
69. Overview of the role of purinergic signaling and insights into its role in cancer therapy
    Francesco Di Virgilio, Valentina Vultaggio-Poma, Mario Tarantini, Anna Lisa Giuliani · 2024 · Pharmacology & Therapeutics
70. Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy
    Zhenyu Xu, Siyan Liu, Yanan Li, Yanping Wu, Jiasheng Tu, Qian Chen, Chunmeng Sun · 2025 · Acta Pharmaceutica Sinica B
71. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors
    Lijun Sun · 2020 · Expert Opinion on Drug Discovery
72. Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling
    Chih-Ta Chen, Peihua Wu, Chia-Chi Hu, Hsiao‐Ching Nien, Jann‐Tay Wang, Jin‐Chuan Sheu, Lu‐Ping Chow · 2021 · International Journal of Molecular Sciences
73. Nociceptor-derived Reg3γ prevents endotoxic death by targeting kynurenine pathway in microglia
    Erika Sugisawa, Takeshi Kondo, Yutaro Kumagai, Hiroki Kato, Yasunori Takayama, Kayako Isohashi, Eku Shimosegawa, Naoki Takemura, Yoshinori Hayashi, Takuya Sasaki et al. · 2022 · Cell Reports
74. Natural Product-Inspired Pyranonaphthoquinone Inhibitors of Indoleamine 2,3-Dioxygenase-1 (IDO-1)
    D. J. Bridewell, J. Sperry, Jason R. Smith, Priambudi Kosim-Satyaputra, Lai-Ming Ching, J. Jamie, M. Brimble · 2013 · Australian Journal of Chemistry
75. 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis
    Elizabeth Pigott, James B. DuHadaway, Alexander J. Muller, Susan K. Gilmour, George C. Prendergast, Laura Mandik‐Nayak · 2014 · Autoimmunity
76. Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches
    Yi Zou, Yan Wang, Fang Wang, Minghao Luo, Yuezhen Li, Wen Liu, Zhangjian Huang, Yihua Zhang, Wenjie Guo, Qiang Xu et al. · 2017 · European Journal of Medicinal Chemistry
77. 1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 while Enhances Lymphocytes NF-κβ2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma
    Murad Alahdal, Yun Xing, Tingting Tang, Jin Liang · 2018 · Scientific Reports
78. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents
    Hui Wen, Yuke Liu, Shufang Wang, Ting Wang, Gang Zhang, Xiaoguang Chen, Yan Li, Huaqing Cui, Fangfang Lai, Sheng Li · 2019 · Molecules
79. Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice
    Jennifer M. Curry, Dahlia M. Besmer, Timothy K. Erick, Nury Steuerwald, Lopamudra Das Roy, Priyanka Grover, Shanti G. Rao, Sritama Nath, Jacob W. Ferrier, Robert W. Reid et al. · 2019 · PLoS ONE
80. High expression of IMPACT protein promotes resistance to indoleamine 2,3‐dioxygenase‐induced cell death
    Darya Habibi, Reza B. Jalili, Farshad Forouzandeh, Christopher John Ong, Aziz Ghahary · 2010 · Journal of Cellular Physiology
81. Detection of kynurenine modifications in proteins using a monoclonal antibody
    Magdalena Maria Staniszewska, Ram H. Nagaraj · 2007 · Journal of Immunological Methods
82. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
    Wang, Yuan, Hu, Guo-fang, Wang, Zhehai · 2017 · OncoTargets and Therapy
83. Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies
    Kehua Jiang, Qing Wang, Xiao‐Long Chen, Xiaodong Wang, Xiaoya Gu, Shuangshuang Feng, Jian Wu, Haojie Shang, Xiaozhuo Ba, Y Zhang et al. · 2024 · International Journal of Nanomedicine
84. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes
    Tamkin Ahmadzada, Kenneth Maan Liong Lee, Candice Julie Clarke, Wendy A. Cooper, Anthony Linton, Brian C. McCaughan, Rebecca Asher, Stephen John Clarke, Glen Reid, Steven Kao · 2019 · Lung Cancer
85. Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
    Hongchuan Zhao, Pu Sun, Wei Guo, Yi Wang, Ao Zhang, Linghua Meng, Chunyong Ding · 2019 · Molecules
86. Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
    Shuguang Ma, Julia Suchomel, Evelyn Yanez, Edward Yost, Xiaorong Liang, Rui Zhu, Hoa Thi Le, Nicholas Siebers, Lori Joas, Roland Morley et al. · 2019 · British Journal of Clinical Pharmacology
87. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
    Felix Popp, Ingracia Capino, Joana Bartels, Alexander Ioannis Damanakis, Jiahui Li, Rabi Raj Datta, Heike Löser, Yue Zhao, Alexander Quaas, Philipp Lohneis et al. · 2021 · Cancers
88. Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
    Aung Naing, Alain Patrick Algazi, Gerald Steven Falchook, Ben Creelan, John D. Powderly, Seth David Rosen, Minal A. Barve, Niharika B. Mettu, Pierre L. Triozzi, John Turner Hamm et al. · 2022 · Cancer
89. Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy
    Zhiren Wang, Wenpan Li, Yanhao Jiang, Tuyen Ba Tran, Jinha Chung, Minhyeok Kim, Aaron James Scott, Jianqin Lu · 2024 · Biomaterials
90. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling
    Haiyu Zhang, Tingting Ge, Xiaoming Cui, Yan Hou, Chaofu Ke, Meng Yang, Kai Ge Yang, Jingtao Wang, Bing Guo, Fan Zhang et al. · 2014 · Molecular BioSystems
91. Immunological effects of chemotherapy in spontaneous breast cancers
    Guido Kroemer, Lorenzo Galluzzi, Laurence Zitvogel · 2013 · OncoImmunology
92. Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma
    Qiyi Zhao, Peipei Wang, Zhanlian Huang, Liang Peng, Chaoshuang Lin, Zhiliang Gao, Shicheng Su · 2016 · Oncotarget
93. Targeting of the innate immunity/inflammation as complementary anti-tumor therapies
    Giovanni Germano, Alberto Mantovani, Paola Allavena · 2011 · Annals of Medicine
94. The Significance of NAD+ Biosynthesis Alterations in Acute Kidney Injury
    Amanda J. Clark, Marie Christelle Saadé, Samir M. Parikh · 2022 · Seminars in Nephrology
95. Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase
    Benjamin Weber, Elena Nickel, Michael Horn, Karin Nienhaus, Gerd Ulrich Nienhaus · 2014 · The Journal of Physical Chemistry Letters
96. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
    Diwakar Davar, Nathan Bahary · 2018 · Targeted Oncology
97. The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy
    Huan Zhao, Yuanqi Li, Dan Wei, Hongrong Luo · 2018 · Journal of Immunology Research
98. Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase
    Shixian Hua, Feihong Chen, Xinyi Wang, Shaohua Gou · 2020 · European Journal of Medicinal Chemistry
99. IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma
    Ruidi Jiao, Xiaoli Zheng, Yanan Sun, Zhuo Feng, Shuai Song, Hong Ge · 2020 · Frontiers in Oncology
100. Immunity, immunotherapy, and rectal cancer: A clinical and translational science review
     Ebunoluwa E. Otegbeye, Jonathan B. Mitchem, Haeseong Park, Aadel A. Chaudhuri, Hyun Jee Kim, Matthew G. Mutch, Matthew A. Ciorba · 2020 · Translational research